

suggest a possible link between the inflammatory response and the development of hypertension. This is the first study to demonstrate the anti-hypertensive effects of IL-10, which might be a key molecule to explain this relationship. Exploring the mechanisms underlying the effects of IL-10 would provide new molecular targets for refractory hypertension and its sequelae.

In conclusion, the sustained IL-10 expression achieved by the single AAV-IL-10 injection ameliorated CHF and prolonged survival in DS rats. IL-10 expression attenuated salt-sensitive hypertension, LV remodelling and renal dysfunction. These results suggest that our IL-10-based strategy potentially prevents the progression of refractory hypertensive organ damage in humans.

Acknowledgements

We thank Miyoko Mitsui and Takako Takagi for their encouragement and technical support. This work was supported by grants from the Ministry of Health, Labour and Welfare of Japan. This work was also supported by Grants-in-Aid for Scientific Research; a grant from the 21 Century COE program; and High-Tech Research Centre Project for Private Universities, matching fund subsidy, from the Ministry of Education, Culture, Sports, Science and Technology of Japan; and a research award to Jichi Medical School Graduate Student. This work was performed at Jichi Medical University in Shimotuke-shi, Tochigi, Japan.

References

- Levine B, Kalman J, Mayer L, et al. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. *N Engl J Med* 1990; **323**: 236–241.
- Vasan RS, Sullivan LM, Roubenoff R, et al. Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: the Framingham Heart Study. *Circulation* 2003; **107**: 1486–1491.
- Mattson DL, James L, Berdan EA, et al. Immune suppression attenuates hypertension and renal disease in the Dahl salt-sensitive rat. *Hypertension* 2006; **48**: 149–156.
- Tian N, Gu JW, Jordan S, et al. Immune suppression prevents renal damage and dysfunction and reduces arterial pressure in salt-sensitive hypertension. *Am J Physiol Heart Circ Physiol* 2007; **292**: H1018–H1025.
- Chung ES, Packer M, Lo KH, et al. Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor- α , in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. *Circulation* 2003; **107**: 3133–3140.
- Mann DL, McMurray JJ, Packer M, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). *Circulation* 2004; **109**: 1594–1602.
- Elenkov IJ, Chrousos GP. Stress hormones, proinflammatory and antiinflammatory cytokines, and autoimmunity. *Ann NY Acad Sci* 2002; **966**: 290–303.
- Cattaruzza M, Slodowski W, Stojakovic M, et al. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. *J Biol Chem* 2003; **278**: 37874–37880.
- Selzman CH, McIntyre RC Jr, Shames BD, et al. Interleukin-10 inhibits human vascular smooth muscle proliferation. *J Mol Cell Cardiol* 1998; **30**: 889–896.
- Ito T, Okada T, Miyashita H, et al. Interleukin-10 expression mediated by an adeno-associated virus vector prevents monocrotaline-induced pulmonary arterial hypertension in rats. *Circ Res* 2007; **101**: 734–741.
- Nishio R, Matsumori A, Shioi T, et al. Treatment of experimental viral myocarditis with interleukin-10. *Circulation* 1999; **100**: 1102–1108.
- Palaniyandi SS, Watanabe K, Ma M, et al. Inhibition of mast cells by interleukin-10 gene transfer contributes to protection against acute myocarditis in rats. *Eur J Immunol* 2004; **34**: 3508–3515.
- Kihara Y, Sasayama S. Transition from compensatory hypertrophy to dilated failing left ventricle in Dahl-lwai salt-sensitive rats. *Am J Hypertens* 1997; **10**: 78S–82S.
- Okada T, Shimazaki K, Nomoto T, et al. Adeno-associated viral vector-mediated gene therapy of ischemia-induced neuronal death. *Methods Enzymol* 2002; **346**: 378–393.
- Matsumita T, Elliger S, Elliger C, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. *Gene Ther* 1998; **5**: 938–945.
- Okada T, Nomoto T, Yoshioka T, et al. Large-scale production of recombinant viruses by use of a large culture vessel with active gassing. *Hum Gene Ther* 2005; **16**: 1212–1218.
- Nakahara T, Hashimoto K, Hirano M, et al. Acute and chronic effects of alcohol exposure on skeletal muscle c-myc, p53, and Bcl-2 mRNA expression. *Am J Physiol Endocrinol Metab* 2003; **285**: E1273–1281.
- Ueno S, Ohki R, Hashimoto T, et al. DNA microarray analysis of in vivo progression mechanism of heart failure. *Biochem Biophys Res Commun* 2003; **307**: 771–777.
- Stumpf C, Lehner C, Yilmaz A, et al. Decrease of serum levels of the anti-inflammatory cytokine interleukin-10 in patients with advanced chronic heart failure. *Clin Sci (Lond)* 2003; **105**: 45–50.
- Ito T, Ikeda U. Inflammatory cytokines and cardiovascular disease. *Curr Drug Targets Inflamm Allergy* 2003; **2**: 257–265.
- Yoshioka T, Okada T, Maeda Y, et al. Adeno-associated virus vector-mediated interleukin-10 gene transfer inhibits atherosclerosis in apolipoprotein E-deficient mice. *Gene Ther* 2004; **11**: 1772–1779.
- Hauk B, Chen L, Xiao W. Generation and characterization of chimeric recombinant AAV vectors. *Mol Ther* 2003; **7**: 419–425.
- Ito T, Okada T, Mimuro J, et al. Adeno-associated virus-mediated prostacyclin synthase expression prevents pulmonary arterial hypertension in rats. *Hypertension* 2007; **50**: 531–536.
- Mu W, Ouyang X, Agarwal A, et al. IL-10 suppresses chemokines, inflammation, and fibrosis in a model of chronic renal disease. *J Am Soc Nephrol* 2005; **16**: 3651–3660.
- Saito Y, Nakao K, Arai H, et al. Augmented expression of atrial natriuretic polypeptide gene in ventricle of human failing heart. *J Clin Invest* 1989; **83**: 298–305.
- de Boer RA, Henning RH, Suurmeijer AJ, et al. Early expression of natriuretic peptides and SERCA in mild heart failure: association with severity of the disease. *Int J Cardiol* 2001; **78**: 5–12.
- Ichihara S, Obata K, Yamada Y, et al. Attenuation of cardiac dysfunction by a PPAR- α agonist is associated with down-regulation of redox-regulated transcription factors. *J Mol Cell Cardiol* 2006; **41**: 318–329.
- Kuwahara F, Kai H, Tokuda K, et al. Hypertensive myocardial fibrosis and diastolic dysfunction: another model of inflammation? *Hypertension* 2004; **43**: 739–745.
- Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. *N Engl J Med* 1994; **331**: 1286–1292.
- Kuwahara F, Kai H, Tokuda K, et al. Transforming growth factor-beta function blocking prevents myocardial fibrosis and diastolic dysfunction, in pressure-overloaded rats. *Circulation* 2002; **106**: 130–135.
- Chrysohoou C, Pitsavos C, Panagiotakos DB, et al. Association between prehypertension status and inflammatory markers related to atherosclerotic disease: the ATTICA Study. *Am J Hypertens* 2004; **17**: 568–573.

Adeno-associated virus vector-mediated production of hepatocyte growth factor attenuates liver fibrosis in mice

Kazuhiro Suzumura · Tadamichi Hirano · Gakuhei Son · Yuji Iimuro · Hiroaki Mizukami · Keiya Ozawa · Jiro Fujimoto

Received: 5 July 2007 / Accepted: 17 October 2007 / Published online: 22 December 2007
© Asian Pacific Association for the Study of the Liver 2007

Abstract

Purpose Adeno-associated virus (AAV) vectors can achieve long-term gene expression and are now feasible for use in human gene therapy. We constructed hepatocyte growth factor (HGF) expressing AAV (AAV5-HGF) and examined its effect in two mouse hepatic fibrosis models.

Methods A model of hepatic fibrosis was established by carbon tetrachloride (CCl₄) administration in Balb/c mice. After the establishment of liver fibrosis, AAV5-HGF was injected once into the portal vein. Mice were killed 3, 6, 9, and 12 weeks after injection. Another model was established by bile duct ligation (BDL). Seven weeks after AAV5-HGF injection, mice underwent BDL, and were then killed 2 weeks after BDL.

Results Mice that received AAV5-HGF achieved stable HGF expression both in the serum and liver for at least 12 weeks. In both models, significant improvement of the liver fibrosis was found in all mice receiving AAV5-HGF based on Azan-Mallory staining. Suppression of hepatic stellate cells (HSC) was confirmed by immunohistochemistry. Fibrogenic markers were significantly suppressed and collagenase activity increased in the livers of mice receiving AAV5-HGF.

Conclusions A single injection of AAV vector containing HGF gene achieved long-term expression of HGF and

resulted in resolution of mouse liver fibrosis. HGF gene therapy mediated by AAV is feasible for the treatment of liver fibrosis.

Keywords HGF · Liver fibrosis · AAV · CCl₄ · BDL

Abbreviations

AAV Adeno-associated virus
BDL Bile duct ligation
CCl₄ Carbon tetrachloride
HGF Hepatocyte growth factor

Introduction

Liver fibrosis is induced by the wound healing response to chronic liver injury caused by hepatitis virus infections, alcohol abuse, prolonged biliary obstruction, hepatotoxic drugs, or metabolic diseases [1]. It is a major cause of morbidity and mortality worldwide, with no effective therapy except for liver transplantation. The main characteristic of liver fibrosis is the excess production and deposition of extracellular matrix (ECM) caused by activated hepatic stellate cells (HSC), portal fibroblasts, and myofibroblasts of bone marrow origin. These cells are activated by fibrogenic cytokines, like transforming growth factor (TGF)- β [2]. Liver fibrosis was considered to be an irreversible end result, but recent studies have demonstrated that liver fibrosis is reversible after clearance of hepatitis C virus (HCV) with either interferon or pegylated interferon, with or without the addition of ribavirin [3–6]. These reports demonstrate the reversibility of human liver fibrosis.

K. Suzumura · T. Hirano · G. Son · Y. Iimuro · J. Fujimoto (✉)
First Department of Surgery, Hyogo College of Medicine,
1-1 Mukogawacho, Nishinomiya, Hyogo 663-8501, Japan
e-mail: sfujimo@hyo-med.ac.jp

H. Mizukami · K. Ozawa
Division of Genetic Therapeutics, Center for Molecular
Medicine, Jichi Medical University, Shimotsuke,
Tochigi 329-0498, Japan

Prior to these reports, the *in vivo* therapeutic effect of hepatocyte growth factor (HGF) against liver fibrosis was shown. The HGF identified and cloned as a 69-kDa α -chain and a 34-kDa β -chain, initially was characterized as a potent mitogen for hepatocytes [7, 8]. HGF also shows mitogenic, motogenic, and morphogenic activities in a wide variety of cell types [9]. Several *in vivo* approaches have shown that HGF plays an essential role in both the development and regeneration of liver [10] and have demonstrated antiapoptotic and cytoprotective effects in hepatocytes [11]. The first report demonstrating the effect of HGF on liver fibrosis used recombinant HGF injection [12]. However, a large amount of recombinant HGF was required, because HGF is unstable in blood, with a half-life of 3–5 min [13, 14]. In order to overcome this problem, we demonstrated HGF gene therapy using hemagglutinating virus of Japan (HVJ) liposomes [15]. The HGF gene transfection into rat skeletal muscle dramatically improves liver fibrosis; however, this strategy also requires repetitive transfections to achieve persistent expression because HVJ-liposome-mediated gene expression is transient [16]. From a clinical point of view, development of a novel gene transfer strategy to achieve long-term expression of HGF protein *in vivo* is crucial. Therefore, we assessed the therapeutic efficacy of adeno-associated virus (AAV) vector-mediated HGF gene therapy for liver fibrosis.

AAV includes a number of small single-stranded DNA viruses and members of the parvovirus family. A number of unique properties make AAV a very promising vector for gene therapy. The advantages of the use of AAV-based vectors are that they can transduce therapeutic genes into both dividing and nondividing cells and achieve long-term gene expression with no apparent adverse effect [17, 18]. In this study, we constructed a recombinant AAV vector coding the human HGF gene (AAV-HGF) and assessed its therapeutic effects for hepatic fibrosis using two mouse models of hepatic fibrosis.

Materials and methods

Cell culture

The human HCC cell line, HepG2, was grown in Dulbecco modified Eagle medium (DMEM) with 10% fetal bovine serum (FBS), 100 U/ml penicillin, and 100 mg/ml streptomycin.

Animals

Male Balb/c mice (6-week-old) were purchased from Japan CLEA, and were maintained in a pathogen-free facility at

Hyogo College of Medicine (Nishinomiya, Hyogo, Japan). The animal experiments were performed in accordance with the guidelines of the National Institutes of Health (Bethesda, MD, U.S.A.), as specified by the animal care policy of Hyogo College of Medicine.

Plasmid AAV5-HGF construction

We first evaluated vectors derived from AAV serotypes 1, 2, and 5. LacZ gene expression recombinant AAV vectors (AAV1-LacZ, AAV2-LacZ, or AAV5-LacZ) were transduced into mouse livers using the same method described below, and efficiency of gene expression was determined by LacZ staining. Among these vectors, AAV5-LacZ had the highest LacZ expression (unpublished result). On the basis of this result, we selected the AAV serotype 5 for the present study and constructed the AAV5-HGF vector. Plasmid AAV5-HGF was constructed by inserting the full-length cDNA of human HGF [19], representing about 2.2 kb, at the *Hinc* II site of the AAV5-MCS that included the CMV promoter and inverted terminal repeat sequence.

AAV5-HGF vector preparation

Plasmids for AAV vector production were purchased from Stratagene (La Jolla, CA, USA). pAAV5-CMV-LacZ, a plasmid encoding LacZ, and 5RepCapA, a helper plasmid for AAV serotype 5, were generous gifts from Dr J. A. Chiorini (National Institutes of Health, Bethesda, MD, USA) [20]. pAAV5-CMV-HGF containing the HGF sequence was prepared as previously described, with the inverted terminal repeat (ITR) sequences changed to those of the AAV5 vector. Recombinant AAV vector stocks were prepared in accordance with an adenovirus-free triple-plasmid transfection protocol [21]. After harvest, vector solutions were purified twice on a cesium chloride (CsCl) gradient and quantified by DNA dot blot hybridization. The same vector stock was used in the same series of experiments to minimize the variability that could occur as a result of the potential differences in vector potency.

AAV vector transduction *in vitro*

In order to confirm HGF expression *in vitro*, HepG2 cells (2×10^5) were plated in 6-cm plastic dishes. After 24 h, cells were infected with 10^6 or 2×10^6 vector genomes of AAV5-HGF. Forty-eight hours after transduction, culture medium and cell lysates were harvested. AAV5-LacZ was transfected into HepG2 cells using the same procedure as that for a control vector. Protein concentrations of human

HGF were determined by enzyme-linked immunosorbent assay (ELISA) using an IMMUNIS human HGF enzyme immunoassay kit (Institute of Immunology, Tokyo, Japan).

Experimental animal models

Liver fibrosis was induced by carbon tetrachloride (CCl₄) [22] or bile duct ligation (BDL) [23]. In the first model, 40 BALB/c mice received CCl₄ by intragastric administration of 5% CCl₄ at a dose of 2 ml/kg body weight (Wako, Tokyo, Japan) dissolved in olive oil, once a week for 16 weeks. After the establishment of liver fibrosis, AAV5-HGF (*n* = 20) or AAV5-LacZ (*n* = 20), at a dose of 10¹¹ vector genomes were transfected into the portal vein through the splenic hilum. Mice were killed at 3, 6, 9, or 12 weeks after transfection (*n* = 5, each point). The second model was created by BDL. Mice were transfected with AAV5-HGF (*n* = 5) or AAV5-CMV-LacZ (*n* = 5) at day 0 by the same procedure described above. Seven weeks after transfection, BDL was performed on all mice. Briefly, the common bile duct was double-ligated using 4-0 silk through a midline abdominal incision. All mice were killed 2 weeks after BDL, and liver and blood were collected for histologic and protein analyses. All mice were anesthetized with ether during AAV transduction, BDL, and at death. The time schedule is shown in Fig. 1.

Histologic examination and immunostaining

Paraffin-embedded tissues were fixed and embedded in paraffin. The sections were stained with Azan-Mallory for collagen visualization. Hepatic fibrosis was assessed in a blinded manner by image analysis, using a planimetric method and the Automatic Image Analysis System (Carl Zeiss, Oberkochen, Germany). For immunohistochemical analysis, the sections were pretreated through deparaffinization, antigen unmasking, and blocking with 1% H₂O₂ for

10 min and 1.5% goat normal serum for 60 min. The specimens were incubated with mouse antihuman α -smooth muscle antibody (α -SMA) (1:100 dilution; Thermo Fisher Scientific, Waltham, MA, USA) for 60 min. After washing, the sections were incubated with biotin-conjugated anti-mouse IgG secondary antibody (1:5000) for 60 min, then with DAB for 1 min and counterstained with hematoxylin for 10 s.

RNA isolation and cDNA synthesis

Total RNA was extracted from mice livers using ISOGEN (Nippon Gene, Tokyo, Japan). The concentration of RNA was spectrophotometrically determined, and the integrity of samples was confirmed by visualizing the 28S and 18S ribosomal RNA bands under ultraviolet light after agarose gel electrophoresis. One microgram of total RNA was reverse transcribed with random primers using a commercial cDNA kit (High-capacity cDNA Archive kit; Applied Biosystems, Foster City, CA, USA). The resulting synthesized cDNA was used for real-time polymerase chain reaction (PCR).

Real-time PCR

Serial dilutions of cDNA were made to determine the linear range for amplification. Real-time PCR was performed on the ABI PRISM 7900HT Sequence Detection System using TaqMan Universal PCR Master Mix and Assays-on-Demand Gene Expression Assay (Collagen α 1(I), α -SMA, TGF- β , TIMP, and MMP13; Applied Biosystems) for the PCR step. A standard curve for serial dilutions of 18S rRNA was similarly generated.

In situ zymography

At the final timepoint, mice livers were removed and embedded in OCT compound (Sakura Finetechnical, Tokyo, Japan). They were cut into 6- μ m frozen sections, and put onto gelatin-coated film (MMP in situ Zymo-Film, Wako Chemical, Osaka, Japan) and incubated at 37°C for 17 h. Gelatin left undegraded on the film was stained with Biebrich Scarlet Stain Solution (Wako Chemical).

Statistical analysis

Data are expressed as mean \pm SD, and the statistical significance of differences among groups was assessed




Fig. 1 Schedule of AAV5-HGF or AAV5-LacZ transduction (a: CCl₄ mice model, b: BDL mice model)

by Student's *t* test. *P* values < 0.05 were regarded as statistically significant.

Results

HGF expression in vitro

HepG2 cells (2×10^5) were infected with AAV5-LacZ (10^6 vector genomes) or AAV5-HGF (10^6 or 2×10^6 vector genomes) for 48 h. Cell lysates and culture medium were harvested at 48 h after infection, and human HGF expression was measured by ELISA. Dose-dependent expression of human HGF was detected in HepG2 cells with AAV5-HGF vector (0.10 ± 0.05 ng/ml in medium and 1.08 ± 0.12 ng/ml in cell lysates using 2×10^6 vector genomes), but no expression was observed in HepG2 cells transfected with AAV5-LacZ vector.

Human HGF expression by AAV5-HGF transduction in CCl₄-treated mice

The human HGF concentrations in the plasma or livers of CCl₄-treated mice were measured by ELISA up to 12 weeks after injection of AAV5-HGF vectors. Human HGF concentrations gradually increased and reached the peak values (25 ± 11 pg/ml in plasma and 250 ± 90 pg/g in the liver) 9 weeks after transduction. The level of HGF persisted for at least 12 weeks after transduction both in the serum and liver. No human HGF expression was found in mice that were transduced with AAV5-LacZ vectors (Fig. 2a and b). Endogenous HGF level was also measured by ELISA. At 12 weeks after AAV5-LacZ transduction, endogenous HGF level of AAV5-LacZ-transduced mice ($n = 5$) was 2.8 ± 0.29 ng/ml in plasma and 87.3 ± 13.7 ng/g in the liver. Endogenous HGF level of CCl₄-treated mice without gene transduction ($n = 5$) was 2.3 ± 0.51 ng/ml in plasma and 79.3 ± 4.72 ng/g in the liver.

Effects of HGF on CCl₄-induced hepatic fibrosis

In order to assess the effect of HGF on liver fibrosis, mice received CCl₄ by intragastric administration once a week for 16 weeks. Four weeks after CCl₄ administration began, mice were transduced once with AAV5-HGF or AAV5-LacZ. Azan-Mallory staining demonstrated that moderate bridging fibrosis was observed in the livers of both AAV5-HGF- and AAV5-LacZ-transduced mice up to 6 weeks after transduction (Fig. 3a, b, e, f). However, AAV5-HGF markedly attenuated fibrosis at 9 or 12 weeks after transduction (Fig. 3g and h) compared with control vector (Fig. 3c and d). Quantitative analysis of the fibrosis by image analysis showed a 50% reduction in fibrosis after AAV5-HGF transduction (Fig. 3i). Immunostaining for α -SMA was performed to detect activated HSC. Expression of α -SMA in the liver was increased in AAV5-LacZ-transduced mice (Fig. 4a–d). This expression was observed up to 6 weeks after AAV5-HGF transduction (Fig. 4e and f), but was suppressed after 9 and 12 weeks of transduction (Fig. 4g and h).

Effects of HGF on hepatic fibrosis induced by bile duct ligation

In order to assess the effect of HGF on liver fibrosis induced by BDL, mice were transduced with AAV5-HGF or AAV5-LacZ. Seven weeks after transduction, BDL was performed on all mice. Mice were killed 2 weeks after BDL to investigate the potential effect of HGF. At the time of death (9 weeks after AAV5-HGF transduction), plasma and liver human HGF concentrations were similar to those seen in the CCl₄ model (16 ± 5 pg/ml in plasma and 224 ± 76 pg/g in the liver). Histologic analysis showed extensive peribiliary and interstitial collagen deposition in mice transduced with AAV5-LacZ (Fig. 5a). However, AAV5-HGF transduction largely attenuated these findings after BDL (Fig. 5c). In AAV5-LacZ-transduced mice, α -SMA-positive cells were observed in the periportal areas

Fig. 2 Human HGF concentrations induced by AAV5-HGF transduction in CCl₄-treated mice (a: plasma, b: liver tissue). Human HGF concentrations gradually increased and reached a peak value both in the plasma and in the liver 9 weeks after transduction. Data represent the mean \pm SD ($n = 5$)






Fig. 3 a–h: Azan-Mallory staining of livers from mice treated with CCl_4 after gene transduction. Upper panels, AAV5-LacZ-transduced mouse livers (a: 3 weeks, b: 6 weeks, c: 9 weeks, and d: 12 weeks after AAV-5 LacZ transduction). Lower panels, AAV5-HGF-transduced mouse livers (e: 3 weeks, f: 6 weeks, g: 9 weeks, and h: 12 weeks after AAV-5 HGF transduction). Original magnification $40\times$. (I): Assessment of fibrosis using image analysis techniques, calculating the ratio of connective tissue to the whole area of the liver from mice transduced with AAV5-LacZ or AAV5-HGF. Data are presented as the mean \pm SD (5 fields per mouse, $n = 5$)



(Fig. 5b). The number of these cells was reduced by AAV5-HGF transduction (Fig. 5d).

Fibrogenesis is suppressed in livers of AAV5-HGF-transduced mice

In order to investigate the role of HGF on liver fibrogenesis by CCl_4 or BDL, real-time PCR was performed (Fig. 6). $\text{TGF-}\beta$ is a fibrogenic cytokine that plays a central role in regulating fibrosis. Expression of $\text{TGF-}\beta$ mRNA was significantly suppressed in the liver of AAV5-HGF-transduced mice treated with CCl_4 (Fig. 6a) or BDL (Fig. 6e) mice. Collagen $\alpha 1$ (I) is the major form of collagen produced in fibrosis. The expression of Collagen $\alpha 1$

(I) mRNA was significantly suppressed in the liver of AAV5-HGF-transduced mice treated with CCl_4 (Fig. 6b) or BDL (Fig. 6f). Expression of α -SMA mRNA was significantly suppressed in the livers of AAV5-HGF-transduced mice treated with CCl_4 (Fig. 6c), although a significant difference was not seen in the livers of AAV5-HGF-transduced mice treated with BDL (Fig. 6g). Tissue inhibitor of matrix metalloproteinases-1 (TIMP-1) inhibits collagen degradation by matrix metalloproteinase (MMP) and protects against apoptosis of HSC. The expression of TIMP-1 mRNA was significantly suppressed in the livers of AAV5-HGF-transduced mice treated with either CCl_4 (Fig. 6d) or BDL (Fig. 6h). These data suggest that AAV5-HGF transduction reduces liver fibrogenesis in 2 models of hepatic fibrosis.

Fig. 4 α -SMA immunostaining of livers from mice treated with CCl₄ after gene transduction. Upper panels, AAV5-LacZ-transduced mouse livers (a: 3 weeks, b: 6 weeks, c: 9 weeks, and d: 12 weeks after AAV-5 LacZ transduction). Lower panels, AAV5-HGF-transduced mouse livers (e: 3 weeks, f: 6 weeks, g: 9 weeks, and h: 12 weeks after AAV-5 HGF transduction). Original magnification 40 \times





Fig. 5 Azan-Mallory staining (left panels) and α -SMA immunostaining (right panels) of BDL mouse livers after gene transduction (a, b: AAV-5 LacZ transduction; c, d: AAV-5 HGF transduction). Original magnification 40 \times , insets 100 \times



HGF transduction resolves liver fibrosis

Ets-1 has been shown to modulate transcription of several MMP genes [24, 25], and recent reports have shown that HGF increases collagenase expression in hepatic stellate cells via an Ets-1 transcription factor-dependent manner [26]. The MMP-13 is the interstitial collagenase in rodents that has the capability of degrading fibrillar collagens.

Real-time PCR showed an increase in MMP-13 mRNA with HGF gene transduction in both CCl₄ mice (Fig. 7a) and BDL mice (Fig. 7b). In situ zymography showed extensive gelatin degradation in liver sections of HGF-transduced mice (Fig. 7c and d, right panels) compared with control mice (Fig. 7c and d, left panels). These data suggest that HGF gene transduction stimulates MMP expression followed by resolution of liver fibrosis.





Fig. 6 HSC activation was suppressed by AAV5-HGF transduction in both CCl₄ mice (upper graphs) and BDL mice (lower graphs). At the final time point, total hepatic RNA was extracted. **a** and **e**: TGF-β;

b and **f**: Collagen α1(I); **c** and **g**: α-SMA; **d** and **h**: TIMP-1 mRNA was quantified by real-time PCR. Data represent the mean ± SD (n = 5)

Fig. 7 HGF transduction increases resolution of liver fibrosis. Expression of MMP-13 mRNA in the livers from CCl₄-treated mice (**a**) or BDL mice (**b**). Data represent the mean ± SD (n = 5). In situ zymography from mouse livers from CCl₄ mice (**c**) or BDL mice (**d**). Left panels, AAV5-LacZ-transduced mouse livers. Right panels, AAV5-HGF-transduced mouse livers



Discussion

The present study demonstrates that AAV-mediated long-term HGF expression can be sustained up to 12 weeks by a single AAV5-HGF transduction, and significantly prevents liver fibrosis induced by CCl₄ and BDL. Up to our knowledge, this study is the first report that demonstrates the effect of AAV-mediated HGF gene therapy on liver fibrosis. CCl₄ induces acute liver injury that is attributed to

inflammatory responses originating from CCl₄-derived free radical formation in the liver. Sustained hepatic inflammation by repetitive CCl₄ administration leads to liver fibrosis through the production of fibrogenic cytokines [27, 28]. In contrast, BDL causes biochemical stress and injury of the bile duct epithelium, which is followed by inflammation, epithelial cell proliferation, upregulation of fibrogenic cytokines that activate myofibroblasts in the periductal region, and finally leads to liver fibrosis [23].

Although the mechanisms resulting in liver fibrosis are different in these two animal models, a single round of AAV5-HGF transduction clearly suppressed liver fibrosis in both models.

With respect to the effect of HGF on fibrosis, two mechanisms are hypothesized. One is the suppression of fibrogenesis through inhibition of TGF- β expression. TGF- β has been implicated as a major cause of tissue fibrosis and is a potent inhibitor of hepatocyte growth. TGF- β induces the phenotypic transition of HSC into proliferating myofibroblast-like cells, which enhance production of ECM components [29]. Although the molecular mechanisms remain to be addressed, we previously demonstrated that HGF inhibits TGF- β expression [15] in dimethylnitrosamine (DMN)-treated rats. In this study, the mRNA of TGF- β was also significantly suppressed by HGF transduction in the livers of both CCl₄- and BDL-treated mice. Moreover, expression of α -SMA mRNA, a marker of HSC activation, also was suppressed by HGF transduction. Immunohistochemical staining demonstrated that HGF suppressed protein expression of α -SMA.

Another HGF-mediated mechanism is the resolution of liver fibrosis by increasing collagenase expression. MMPs are a family of extracellular zinc- and calcium-dependent proteases that promote degradation of the ECM components [30]. Ozaki et al. [26] reported that HGF increases MMP-1 promoter activity through increased expression and binding activity of Ets-1 in L190 cells, a human HSC. Ets-1 has been shown to modulate transcription of several MMP genes. In the present study, real-time PCR revealed an increase in MMP-13 mRNA by HGF gene transduction, and in situ zymography showed extensive gelatin degradation in liver sections of HGF-transduced mice. These data strongly suggest that HGF gene transduction stimulated MMP expression, resulting in the resolution of liver fibrosis.

As our and other investigators have reported, HGF has powerful therapeutic effects on liver fibrosis [12, 15, 31–33]. Matsuda et al. [12] reported that the continuous recombinant HGF injection accelerates the recovery from liver cirrhosis. However, a large amount of recombinant HGF is required using this method because HGF has a very short life. Recombinant HGF is very expensive, limiting such use in patients. Gene therapy has the advantage that it could sustain gene expression compared with the administration of recombinant protein. Recent studies have established several gene delivery systems for liver fibrosis. Since adenoviral vectors are capable of powerful gene expression, several reports have used adenoviral vector-mediated HGF gene therapy for liver fibrosis [31–33]. However, because it elicits a host immune response because of the highly immunogenic nature of the virus, it could not be used for repetitive transduction, limiting its clinical use [34, 35]. Nonviral vector systems, such as HVJ-liposome or naked

plasmid administration, do not induce host immune response. However, these vectors require repetitive transduction to sustain gene expression because the expression is transient. Therefore, from a clinical viewpoint, a safe gene transfer method that achieves long-term expression is necessary. AAV vectors are single-stranded DNA viruses that are derived from a replication-deficient member of the parvovirus family. AAV vectors do not contain viral coding sequences and achieve efficient gene transduction in both dividing and nondividing target cells, while eliciting little immunogenicity. Moreover, they can achieve long-term gene expression in vivo [17, 36]. Davidoff et al. recently reported that AAV5-mediated gene expression stably maintained for 2 years in nonhuman primates [37]. In fact, a human clinical trial of an AAV vector has been conducted for the treatment of hemophilia B patients [38, 39]. Therefore, the use of AAV vectors for HGF gene therapy for liver fibrosis is feasible.

The influence of HGF on tumorigenicity should be considered, because the effect of HGF on the growth of HCC is still controversial. Although tumorigenicity has been reported in transgenic mice, overexpressing HGF, HGF expression level was 5000% higher in these mice compared with normal mice [40]. On the other hand, Shiota et al. [41] reported that growth of HCC cell lines was inhibited by the addition of recombinant HGF (50–200 ng/ml). Moreover, transgenic mice that express about 200–300% more HGF than normal mice demonstrate inhibition of neoplastic tumor development [42]. In our present study, human HGF level of HGF-transduced mouse was less than 40 pg/ml in serum, and less than 400 pg/g in liver tissue. We consider that such a low-level HGF concentration may not affect the tumorigenicity of HCC.

In conclusion, we demonstrated that AAV-mediated HGF gene therapy achieved long-term HGF expression, and markedly suppressed hepatic fibrosis induced by CCl₄ or BDL. These results suggest that AAV-HGF-mediated gene therapy may represent a novel strategy for the treatment of patients with progressive liver fibrosis.

Acknowledgements This work was supported by Grant-in-aid for Scientific Research (No. 11470266) from Japan Society for the Promotion of Science and the Ministry of Health.

References

1. Pinzani M, Romanelli RG, Magli S. Progression of fibrosis in chronic liver diseases: time to tally the score. *J Hepatol* 2001;34:764–7.
2. Bataller R, Brenner DA. Liver fibrosis. *J Clin Invest* 2005; 115:209–18.
3. Lindsay KL, Treppe C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. *Hepatology* 2001;34:395–403.

4. Manns MP, McHutchinson JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. *Lancet* 2001;358:958–65.
5. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. For the International Hepatitis Interventional Therapy Group (IHIT). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. *Lancet* 1998;352:1426–32.
6. McHutchinson JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. For the Hepatitis Interventional Therapy Group. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. *N Engl J Med* 1998;339:1485–92.
7. Nakamura T, Nawa K, Ichihara A. Partial purification and characterization of hepatocyte growth factor from serum of hepatectomized rats. *Biochem Biophys Res Commun* 1984;122:1450–9.
8. Nakamura T, Nishizawa T, Hagiya M, Seki T, Shimonishi M, Sugimura A, et al. Molecular cloning and expression of human hepatocyte growth factor. *Nature* 1989;342:440–3.
9. Michalopoulos GK, DeFrances MC. Liver regeneration. *Science* 1997;276:60–6.
10. Boros P, Miller CM. Hepatocyte growth factor: a multi functional cytokine. *Lancet* 1995;345:293–5.
11. Bardelli A, Longati P, Alberio D, Goruppi S, Schneider C, Ponzetto C, et al. HGF receptor associates with anti-apoptotic protein BAG-1 and prevents cell death. *EMBO J* 1996;15:6205–12.
12. Matsuda Y, Matsumoto K, Yamada A, Ichida T, Asakura H, Komoriya Y, et al. Preventive and therapeutic effects in rats of hepatocyte growth factor infusion on liver fibrosis/cirrhosis. *Hepatology* 1997;26:81–9.
13. Kawaida K, Matsumoto K, Shimazu H, Nakamura T. Hepatocyte growth factor prevents acute renal failure and accelerates renal regeneration in mice. *Proc Natl Acad Sci USA* 1994;91:4357–61.
14. Liu KX, Kato Y, Narukawa M, Kim DC, Hanano M, Higuchi O, et al. Importance of the liver in plasma clearance of hepatocyte growth factors in rats. *Am J Physiol* 1992;263:G642–9.
15. Ueki T, Kaneda Y, Tsutsui H, Nakanishi K, Sawa Y, Morishita R, et al. Hepatocyte growth factor gene therapy of liver cirrhosis in rats. *Nat Med* 1999;5:226–30.
16. Hirano T, Fujimoto J, Ueki T, Yamamoto H, Iwasaki T, Morisita R, et al. Persistent gene expression in rat liver *in vivo* by repetitive transfections using HVJ-liposome. *Gene Ther* 1998;5:459–64.
17. Snyder RO, Miao CH, Patijn GA, Spratt SK, Danos O, Nagy D, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. *Nat Genet* 1997;16:270–6.
18. Miao CH, Snyder RO, Schowalter DB, Patijn GA, Donahue B, Winthel B, et al. The kinetics of rAAV integration in the liver. *Nat Genet* 1998;19:13–5.
19. Seki T, Hagiya M, Shimonishi M, Nakamura T, Shimizu S. Organization of the human hepatocyte growth factor-encoding gene. *Gene* 1991;102:213–9.
20. Chiorini JA, Kim F, Yang L, Kotin RM. Cloning and characterization of adeno-associated virus type 5. *J Virol* 1999;73:1309–19.
21. Matsushita T, Elliger S, Elliger C, Podsakoff G, Villarreal L, Kurtzman GJ, et al. Adeno-associated virus vectors can be efficiently produced without helper virus. *Gene Ther* 1998;5:938–45.
22. Paquet KJ, Kamphausen U. The carbon-tetrachloride-hepatotoxicity as a model of liver damage. First report: long-time biochemical changes. *Acta Hepatogastroenterol (Stuttg)* 1975; 22:84–8.
23. Ezure T, Sakamoto T, Tsuji H, Lunz JG 3rd, Murase N, Fung JJ, et al. The development and compensation of biliary cirrhosis in interleukin-6-deficient mice. *Am J Pathol* 2000;156:1627–39.
24. Wasyluk C, Gutman A, Nicholson R, Wasyluk B. The c-Ets oncoprotein activates the stromelysin promoter through the same elements as several non-nuclear oncoproteins. *EMBO J* 1991;10:1127–34.
25. Westermarck J, Seth A, Kahari VM. Differential regulation of interstitial collagenase (MMP-1) gene expression by ETS transcription factors. *Oncogene* 1997;14:2651–60.
26. Ozaki I, Zhao G, Mizuta T, Ogawa Y, Hara T, Kajihara S, et al. Hepatocyte growth factor induces collagenase (matrix metalloproteinase-1) via the transcription factor Ets-1 in human hepatic stellate cell line. *J Hepatol* 2002;36:169–78.
27. Wu J, Norton PA. Animal models of liver fibrosis. *Scand J Gastroenterol* 1996;31:1137–43.
28. Britton RS, Bacon BR. Role of free radicals in liver diseases and hepatic fibrosis. *Hepatogastroenterology* 1994;41:343–8.
29. Border WA, Noble NA. Transforming growth factor beta in tissue fibrosis. *N Engl J Med* 1994;331:1286–92.
30. Nagase H, Woessner JF Jr. Matrix metalloproteinases. *J Biol Chem* 1999;274:21491–4.
31. Ozawa S, Uchiyama K, Nakamori M, Ueda K, Iwahashi M, Ueno H, et al. Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy. *Surgery* 2006;139:563–73.
32. Lin Y, Xie WF, Chen YX, Zhang X, Zeng X, Qiang H, et al. Treatment of experimental hepatic fibrosis by combinational delivery of urokinase-type plasminogen activator and hepatocyte growth factor genes. *Liver Int* 2005;25:796–807.
33. Oe H, Kaido T, Furuyama H, Mori A, Imamura M. Simultaneous transfer of vascular endothelial growth factor and hepatocyte growth factor genes effectively promotes liver regeneration after hepatectomy in cirrhotic rats. *Hepatogastroenterology* 2004;51:1641–7.
34. Li Q, Kay MA, Finegold M, Stratford-Perricaudet LD, Woo SL. Assessment of recombinant adenoviral vectors for hepatic gene therapy. *Hum Gene Ther* 1993;4:403–9.
35. Marshall E. Gene therapy death prompts review of adenovirus vector. *Science* 1999;286:2244–5.
36. Nathwani AC, Davidoff AM, Hanawa H, Hu Y, Hoffer FA, Nikanorov A, et al. Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques. *Blood* 2002;100:1662–9.
37. Davidoff AM, Gray JT, Ng CY, Zhang Y, Zhou J, Spence Y, et al. Comparison of the ability of adeno-associated viral vectors pseudotyped with serotype 2, 5, and 8 capsid proteins to mediate efficient transduction of the liver in murine and nonhuman primate models. *Mol Ther* 2005;11(6):875–88.
38. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. *Nat Genet* 2000;24:257–61.
39. Manno CS, Chew AJ, Hutchison S, Larson PJ, Herzog RW, Arruda VR, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. *Blood* 2003;101:2963–72.
40. Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, et al. Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. *Proc Natl Acad Sci USA* 1997;94:701–6.
41. Shiota G, Rhoads DB, Wang TC, Nakamura T, Schmidt EV. Hepatocyte growth factor inhibits growth of hepatocellular carcinoma cells. *Proc Natl Acad Sci USA* 1992;89:373–7.
42. Santoni-Rugiu E, Preisegger KH, Kiss A, Audolfsson T, Shiota G, Schmidt EV, et al. Inhibition of neoplastic development in the liver by hepatocyte growth factor in a transgenic mouse model. *Proc Natl Acad Sci USA* 1996;93:9577–82.

Protection Against Aminoglycoside-induced Ototoxicity by Regulated AAV Vector-mediated GDNF Gene Transfer Into the Cochlea

Yuhe Liu^{1,2,3}, Takashi Okada^{1,4}, Kuniko Shimazaki⁵, Kianoush Sheykhholeslami⁶, Tatsuya Nomoto¹, Shin-Ichi Muramatsu⁷, Hiroaki Mizukami¹, Akihiro Kume¹, Shuifang Xiao³, Keiichi Ichimura² and Keiyo Ozawa¹

¹Division of Genetic Therapeutics, Jichi Medical University, Tochigi, Japan; ²Department of Otolaryngology, Jichi Medical University, Tochigi, Japan; ³Department of Otolaryngology, Peking University First Hospital, Beijing, China; ⁴Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; ⁵Department of Physiology, Jichi Medical University, Tochigi, Japan; ⁶Department of Neurobiology, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA; ⁷Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan

Since standard aminoglycoside treatment progressively causes hearing disturbance with hair cell degeneration, systemic use of the drugs is limited. Adeno-associated virus (AAV)-based vectors have been of great interest because they mediate stable transgene expression in a variety of postmitotic cells with minimal toxicity. In this study, we investigated the effects of regulated AAV1-mediated glial cell line-derived neurotrophic factor (GDNF) expression in the cochlea on aminoglycoside-induced damage. AAV1-based vectors encoding GDNF or vectors encoding GDNF with an rTA2s-S2 Tet-on regulation system were directly microinjected into the rat cochlea through the round window at 5×10^{10} genome copies/body. Seven days after the virus injection, a dose of 333 mg/kg of kanamycin was subcutaneously given twice daily for 12 consecutive days. GDNF expression in the cochlea was confirmed and successfully modulated by the Tet-on system. Monitoring of the auditory brain stem response revealed an improvement of cochlear function after GDNF transduction over the frequencies tested. Damaged spiral ganglion cells and hair cells were significantly reduced by GDNF expression. Our results suggest that AAV1-mediated expression of GDNF using a regulated expression system in the cochlea is a promising strategy to protect the cochlea from aminoglycoside-induced damage.

Received 12 May 2007; accepted 15 November 2007; published online 8 January 2008. doi:10.1038/sj.mt.6300379

INTRODUCTION

Aminoglycoside antibiotics are frequently used in empiric therapy for serious infections, such as septicemia, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. However, it is well known

that aminoglycosides are associated with severe side effects, such as ototoxicity and nephrotoxicity, which attack the cochlea or vestibule and destroys the auditory and vestibular hair cells that pass information to the auditory nerve.¹ In addition, aminoglycosides predominantly destroy the outer hair cells by ototoxicity. Although the exact mechanism of damage is not well established,² aminoglycoside-induced hair cell loss results in a permanent hearing deficit³ that can progressively occur 6 months to a year after exposure to these drugs. Therefore, the development of a strategy to prevent aminoglycoside-associated ototoxicity before adverse events occur is a critical issue in clinical settings.

The expression of a transgene using viral vectors is a potential approach to introduce neurotrophic factors into the cochlea to prevent and treat aminoglycoside-induced hearing loss. However, most of the currently used vectors, such as adenovirus vectors or herpes simplex virus vectors, have an associated vector-related cytotoxicity.^{4,5} Hence, adeno-associated virus (AAV) vectors may be good candidates for gene transfer into the cochlear cells because of their efficient transduction and their safety and potential in long-term expression.⁶ We have previously demonstrated that an AAV1-based vector efficiently transduced the inner hair cells, the spiral ganglion cells, and many other types of cells.⁷ Therefore, an AAV1-based vector should successfully introduce secretory proteins, such as glial cell line-derived neurotrophic factor (GDNF), into the cochlea to prevent aminoglycoside-induced ototoxicity.

GDNF, a member of the transforming growth factor β family, was initially identified as a survival factor for mid-brain dopaminergic neurons and for a wide range of neuronal populations in the central and peripheral nervous systems.⁸⁻¹⁰ Although it is still unclear whether GDNF protects against ototoxicity, sustained infusion of recombinant GDNF protected the cochlear structure and function from noise- and drug-induced damage and stress,¹¹⁻¹⁸ although its half-life is very short. However, an overdose of GDNF was shown to enhance the sensitivity of the cochlea to insult and

Correspondence: Takashi Okada, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan. E-mail: t-okada@ncnp.go.jp; Keiyo Ozawa, Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. E-mail: kozawa@jichi.ac.jp

to destroy cochlear function.¹² Furthermore, it has been reported that testicular tumors are formed in GDNF-overexpressing mice.¹⁹ Therefore, an appropriate regulation system is required to realize the therapeutic benefits of GDNF expression.

Regulated transgene expression has been successfully achieved in various gene therapy experiments using the Tet system.^{20–23} Notably, tetracycline derivatives, such as doxycycline (Dox), activate the Tet-on system at doses 100-fold lower than tetracycline. Furthermore, the reverse Tet-responsive transcriptional activator (rtTA) series were improved through the generation of variants called rtTA2s-S2, which showed lower leakiness and better inducibility in HeLa cells and mice.^{24,25}

In this study, we describe *in vivo* therapeutic experiments utilizing AAV1 vector-mediated tetracycline-regulated expression of GDNF in cochlea. We demonstrate that AAV1 vector-mediated GDNF expression protects sensory cells in the inner ear from drug-induced degeneration.

RESULTS

Expression and distribution of transgene in the cochlea

AAV1-EGFP or AAV1-GDNF containing either the enhanced humanized green fluorescent protein (EGFP) gene or the GDNF gene under the control of the CAG (human cytomegalovirus (CMV) immediate-early enhancer and Chicken β -actin promoter) promoter, and the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) (Figure 1a), was injected into the cochlea. The GDNF protein level in the perilymph was measured by enzyme-linked immunosorbent assay (Figure 2a). There was a significant increase in GDNF concentration in the cochlea transduced with AAV1-GDNF. The widespread distribution of the GDNF expression was observed in the cochlea, including the spiral ganglion and the inner hair cells (Figure 2b).

To examine the possible transduction of the contralateral ear with the virus diffusion, we analyzed the AAV vector-mediated




Figure 1 Schematic representation of the viral vectors used in this study. (a) An adeno-associated virus 1 (AAV1)-based vector was constructed using the CAG promoter to drive enhanced green fluorescent protein (EGFP) or mouse glial cell line-derived neurotrophic factor (GDNF) with a FLAG tag (GDNFflag). The Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was inserted into the 3' end of the transgene cassette. (b) The transactivator rtTA2s-S2 is under the control of the CMV promoter. The minimal CMV promoter (PminCMV) induces transgene expression (EGFP or GDNFflag) in combination with the Tetracycline-responsive element (TRE) and transactivator. CAG, human cytomegalovirus immediate-early enhancer and Chicken β -actin promoter; CMV, cytomegalovirus immediate-early promoter; pA, the simian virus 40 polyadenylation sequences; ITR, inverted terminal repeat from AAV2.

transgene expression of the rodents with this transduction approach using the optical bioluminescence imaging. Luciferase expression was mainly detected at the injected side of the cochlea (5,370.3 photons/sec/cm²/sr, Supplementary Figure S1). Interestingly, the AAV vector also transduced the contralateral ear (876.8 photons/sec/cm²/sr), along with the brain (792.9 photons/sec/cm²/sr). Similar results were obtained with repeated experiments.

Preservation of the hair cells and spiral ganglion cells in the cochlea

Hair cell loss in the whole-mount cochlea of all the tested rat groups was analyzed by F-actin staining with rhodamine-phalloidin. Figure 3a shows a representative dissection through the second turn of the rat cochlea, in which a full complement of hair cells is revealed by F-actin phalloidin staining. In the vehicle-treated control group, outer hair cells in the base and middle turn were drastically lost after kanamycin treatment (Figure 3b). In the AAV1-GDNF/kanamycin-treated group, successful protection of the hair cells in the cochlea was observed (Figure 3c). In the contralateral cochlea, some of outer hair cells were also protected (Figure 3d). The spiral ganglion cell loss in the basal turn of the cochlea was assessed using 4',6'-diamino-2-phenylindole dihydrochloride staining (Figure 4a and b). Survival of the spiral ganglion cells in the AAV1-GDNF injected cochlea was significantly improved compared to that in the AAV1-EGFP injected cochlea (Figure 4c).

Protection of cochlear function by GDNF

Auditory brain stem response (ABR) recordings of the aminoglycoside-treated animals were performed to examine hearing




Figure 2 Expression and distribution of transgene in the cochlea. (a) Cochlear glial cell line-derived neurotrophic factor (GDNF) expression levels were measured by enzyme-linked immunosorbent assay in the transduced rats. GDNF expression level of the perilymph in the AAV1-GDNF/kanamycin group was significantly higher than that in the control group ($n = 5$, $P < 0.001$). (b) Immunohistochemistry was performed to analyze the expression of the GDNFflag in the rat cochlea. The AAV1-EGFP-transduced cochlea was used as a control (left). Cochlear sections were prepared after AAV1-GDNF injection and kanamycin administration. GDNFflag expression was detected in the cochlea with an anti-FLAG antibody (right). Scale bar = 25 μ m; $\times 400$. AAV1, adeno-associated virus 1; EGFP, enhanced green fluorescent protein.




Figure 3 Preservation of the hair cells in the transduced cochlea. Hair cell loss in the cochlea of transduced rats was analyzed by F-actin staining. The dissected samples were dissected from the middle turn of the cochlea. The adeno-associated virus 1 (AAV1) vector was injected into the scala tympani of the cochlea prior to 12 days of kanamycin administration. (a) The normal cochlea. (b) The cochlea from the vehicle-treated ear; the many dark spaces represent the loss of outer hair cells. (c) The cochlea from the AAV1-GDNF-transduced ear. (d) The cochlea from the contralateral ear of AAV1-GDNF transduced rats. GDNF, glial cell line-derived neurotrophic factor.




Figure 4 Survival of the spiral ganglion cells in the transduced cochlea. AAV1-GDNF-mediated rescue of the kanamycin-induced damage to the rat spiral ganglion neurons (SGNs): 4',6-diamino-2-phenylindole dihydrochloride (DAPI) staining was performed on the sections obtained from the rat pretreated with either AAV1-EGFP or AAV1-GDNF, followed by kanamycin injections. (a, b) Representative photomicrographs of the cryosections showing the basal turn of the cochlear spiral (a, AAV1-EGFP; b, AAV1-GDNF). (c) The number of DAPI-positive large-nucleus cells that exhibited SGN morphology was counted. An asterisk denotes a statistically significant difference between the AAV1-GDNF and AAV1-EGFP-transduced rats (*t*-test, $P < 0.001$). AAV1, adeno-associated virus 1; EGFP, enhanced green fluorescent protein; glial cell line-derived neurotrophic factor.

impairment. At all frequencies tested, both GDNF-transduced and contralateral, untreated ears showed a significant improvement in the threshold shifts compared to the ears transduced with EGFP ($n = 5$, $P < 0.05$) (Figure 5). In the EGFP group, there was




Figure 5 Protection of cochlear function by glial cell line-derived neurotrophic factor GDNF. Auditory brain stem response (ABR) threshold shifts (mean \pm SD) of the (a) treated and (b) untreated ears at each tested frequency in the enhanced green fluorescent protein (EGFP) and GDNF transduced rats. The ABR threshold was measured twice in all the animals. The ears treated with AAV1-GDNF showed a significant improvement in the threshold shifts compared to the ears treated with AAV1-EGFP at all frequencies tested ($n = 5$, $P < 0.05$). Arrows indicate the average ABR thresholds that exceeded the output power of the ABR apparatus. AAV1, adeno-associated virus 1.

no significant difference in the ABR threshold shifts between the transduced and contralateral, untreated cochleae at all frequencies tested. Animals transduced with the AAV1-GDNF demonstrated lower ABR threshold shifts in the injected side compared to the contralateral side (at 12, 16, 20, 24 kHz; $P < 0.05$). These data indicate that both ears were protected even if the AAV1-GDNF was only injected into one ear.

Induced transgene expression

Two hundred and ninety three cells were transduced with the proviral plasmid harboring rTA2s-S2 and the tetracycline-responsive element (TRE) to express the EGFP gene (Figure 1b). In the presence of Dox, a significant level of fluorescence was detected, suggesting that the rTA2s-S2 system could switch on transcription following Dox treatment (Figure 6a). In contrast, reporter gene expression in the cultured cells was faint in the absence of Dox, indicating a low basal activity *in vitro*. Western blot analysis of GDNF showed that the transgene was induced in the presence of Dox, while no expression was detected in the absence of Dox (Figure 6b).

In vivo induction of GDNF expression and the dose-response to Dox

Enzyme-linked immunosorbent assay analysis of the GDNF expression level in muscle also showed low basal activity and induced expression after Dox treatment (Figure 6c). In the absence of Dox, the expression level of GDNF in the AAV2-S2-GDNF group was as low as that in the phosphate-buffered saline and AAV2-LacZ groups. On the other hand, significant increases in the GDNF level were observed in the muscle with increasing amounts of Dox, demonstrating that the rTA2s-S2 system induces gene expression in a dose-dependent manner.

Inducible GDNF expression in the cochlea

Extensive inducible GDNF transgene expression was confirmed by immunohistochemistry using an anti-FLAG-antibody in the AAV1-S2-GDNF/kanamycin group in the presence of Dox (Figure 7).




Figure 6 Induction of the transgene expression. **(a)** HEK293 cells were transfected with the proviral plasmid pAAV2-rtTA2-S2-TRE-d2EGFP, and the expression of enhanced green fluorescent protein (EGFP) was induced by the doxycycline (Dox) (1 µg/ml). **(b)** Western blot analysis with an anti-FLAG antibody to detect the glial cell line-derived neurotrophic factor (GDNF) expression in the transduced 293 cells with the proviral plasmids. pAAV2-GDNF (lane 1), pAAV2-EGFP (lane 2), pAAV2-rtTA2s-2-TRE-GDNF with Dox (lane 3), and pAAV2-rtTA2s-2-TRE-GDNF without Dox (lane 4). **(c)** Dose-response of GDNF in the AAV2-S2-GDNF-injected muscle to the various concentrations of Dox. Mice were injected with phosphate-buffered saline (PBS), AAV2-LacZ, or AAV2-S2-GDNF followed by Dox administered in the drinking water. The mean muscle GDNF concentration in the animals treated with the AAV2-S2-GDNF in the absence of Dox was not significantly different compared to the animals treated with PBS or AAV2-LacZ ($P > 0.05$). The GDNF expression levels in the animals transduced with the AAV2-S2-GDNF significantly increased with increasing Dox concentration ($P < 0.05$). AAV1, adeno-associated virus 1.

In contrast, no detectable GDNF expression was observed in the cochlea of the AAV1-S2-GDNF/kanamycin group in the absence of Dox (data not shown).

Protection of cochlear function with induced GDNF expression

To evaluate the adverse effects of the transduction procedure, ABR recordings were performed on kanamycin-free rats after injection of the inducible AAV1-S2-GDNF vectors and Dox administration. At all frequencies tested, no significant increase in the ABR threshold was observed after virus injection (Figure 8a). This result indicates that AAV1 vector injection, transgene expression, and Dox administration did not affect the ABR threshold of the experimental rats. Interestingly, even if AAV1-S2-GDNF was injected into the cochlea of one ear, the cochleas of both ears were protected in the presence of Dox. In particular, the ABR threshold shifts were significantly improved in both the AAV1-S2-GDNF-injected cochlea of the kanamycin-treated rats in the presence of Dox (Figure 8b)




Figure 7 Expression of the GDNF flag in the rat cochlea. **(a, b, c)** The sections were sampled after the AAV1-S2-GDNF injection into the cochlea in the presence of doxycycline. GDNF flag expression was detected using an anti-FLAG antibody. **(d)** Samples from AAV1-EGFP-inoculated cochlea were analyzed as the negative control. Scale bar = 25 µm; $\times 400$. AAV1, adeno-associated virus 1; GDNF, glial cell line-derived neurotrophic factor; EGFP, enhanced green fluorescent protein.




Figure 8 Protection of cochlear function with induced glial cell line-derived neurotrophic factor (GDNF) expression. **(a)** Auditory brain stem response (ABR) thresholds (mean \pm SD) at each frequency tested in the AAV1-S2-GDNF-injected rat cochlea in the presence of doxycycline (Dox). No significant difference in the hearing thresholds was observed at each frequency between preinjection and postinjection. SPL, sound pressure level. ABR threshold shifts (mean \pm SD) at each tested frequency in the **(b)** transduced or **(c)** nontransduced cochlea with or without Dox. Significant differences in the hearing threshold shifts were observed at each frequency between AAV1-S2-GDNF cochlea in the presence and absence of Dox ($n = 5$, $P < 0.05$). Arrows indicate the average ABR thresholds that exceeded the output power of the ABR apparatus.

and the cochlea of the noninjected contralateral ear (Figure 8c). However, the ABR threshold shifts at all frequencies were significantly lower in the treated group (AAV1-S2-GDNF/kanamycin plus Dox) than in the contralateral, untreated ear.

DISCUSSION

In this study, we showed that both sustained and regulated AAV1-mediated GDNF expression protected the cochlear function of rats from aminoglycoside-induced ototoxicity. Indeed, damaged spiral ganglion cells and hair cells were significantly reduced by

regulated GDNF expression. The ABR monitoring revealed that there was no loss of the cochlear function over the frequencies tested after AAV vector injection and Dox treatment. These data suggest that regulated expression of GDNF in the cochlea efficiently preserves the cochlea from kanamycin-induced ototoxicity.

Among the various viral vector systems, the recombinant AAV-mediated gene transduction system offers several important advantages as a tool for direct somatic gene delivery into the cochlea. These include long-term stable expression of therapeutic genes in a wide variety of postmitotic tissues and minimal vector-related cytotoxicity.²⁶ In our previous report, we demonstrated the effective transduction of mouse cochleae with the AAV1-based vectors.⁷ Generally the therapeutic effectiveness depends on an appropriate concentration and the half-life of the molecules. AAV vector-mediated gene transfer is a promising delivery technique to facilitate a long-term and chronic supply of therapeutic proteins that have a short half-life, such as GDNF. Furthermore, when the CAG promoter is used, efficient transduction activity is observed in the cochlear cells including the inner hair cells and spiral ganglion cells.^{27,28}

Our data showed that AAV1-GDNF-mediated transduction of the rat cochleae provided significant protection of the cochlea against aminoglycoside-induced damage. This finding is consistent with previous studies that have used adenovirus-mediated GDNF expression^{13,15,16} and demonstrates the feasibility of gene therapy with AAV1-based vectors for drug-induced hearing loss. Although the exact mechanism has not yet been elucidated, antioxidant pathways might be involved in the protective function of GDNF in the inner ear.²⁹ Free-radical formation following exposure to aminoglycoside is considered one of the major mechanisms to explain the aminoglycoside-related hair cell death.^{1,30,31} It has been previously shown that GDNF is endogenously synthesized in the inner hair cells and spiral ganglion cells of the cochlea,³² and the two known GDNF receptors are present in the spiral ganglion.^{17,22,33} In the present study, we inoculated the cochlea with the AAV1 vectors via the round window membrane and detected a high level of transgene expression mainly in the inner hair cells and spiral ganglion cells. The AAV1-mediated GDNF expression pattern was similar to that of the endogenous protein; therefore GDNF supplemented *in situ* can play a substantial role in protection. Although the transduction of the *GDNF* gene was not observed in outer hair cells, GDNF levels in the perilymph of the manipulated cochleae was much higher than in the control cochleae. These cells may respond to the secretion of another growth factor that promotes hair cell survival. Upregulation of GDNF in inner hair cells and spiral ganglion cells following noise also support this concept.³⁴

Compared to the vehicle controls, increased cochlear cell survival was observed in the contralateral ears of the AAV1-GDNF group, suggesting that the contralateral cochleae in treated rats were also moderately protected. Expression of the transgene was detected in the contralateral cochlea of the rats after injection with 5×10^{10} genome copies of AAV1 per cochlea (data not shown). AAV can diffuse from one ear to the other via the cerebrospinal fluid in rodents.³⁵ Therefore, secreted GDNF molecules may also diffuse and exert a protective effect in the opposite ear. Alternatively, GDNF might enhance the neuronal activity (either afferent or efferent) of both ears, protecting both the treated and

the contralateral cochlear function. Moreover, since infusion of the vectors into the cochlea forces large amounts of the vectors into the cerebrospinal fluid, any functional effect might be associated with the transduction of the brain. In this context, it is of great interest to know whether the otoprotective effect was achieved by the simple diffusion of the transgene product or direct transduction of the cells in the contralateral ear. To answer this question, we analyzed the local expression of the nonsecretory protein marker in the rodents with this transduction approach. Consequently, we feel that the direct transduction of the cells in the contralateral ear might be involved in the neuroprotection.

The present results showed that AAV-mediated delivery of a Tet-on system was able to control transgene expression. This Tet-on system incorporates the mutant transactivator rTA2s-S2 and the transgene in which messenger RNA transcription is activated in the presence of an inducer, leading to protein expression. As we showed, the inducible expression of GDNF efficiently protected the cochlear structure and function from kanamycin-induced damage. GDNF was overexpressed in the induced state with the rTA2s-S2 system, whereas GDNF expression was nearly normal in the non-induced state. In our study, cochlear function was significantly protected from aminoglycoside-induced cochlear damage in the presence of Dox. Although intracochlear injections did not affect physiological cochlear function, intramuscular injections of the vectors expressing Dox-dependent activators may elicit a cellular and humoral response against the transactivator in nonhuman primates.³⁶⁻³⁸ The use of tissue-specific promoters that restrict transgene expression to nonprofessional antigen-presenting cells, and the use of AAV vectors, may reduce the induction of a specific T-cell response.³⁹

Another attractive feature of the Tet-on system is the high safety profile of the inducer. In our study, Dox was orally administered to the rats to induce GDNF expression. Transgene expression levels were dependent on the dose of Dox, and the dose range of this inducer was below the normal bactericidal treatment levels used in similarly sized animals.^{40,41} Furthermore, a Dox regimen in mice that is proportional to a clinically accepted dose of the drug in humans causes a significant induction of transgene expression.

Sequences of antibiotic administration and withdrawal to reverse the Dox induction of therapeutic gene expression were demonstrated in previous studies.^{25,42} However, the aminoglycoside-induced hearing impairment model is not an appropriate model for adding and removing the Dox diet because the insulting phase is too short to successively induce and repress the Tet-on system. Furthermore, treatment of age-related hearing loss or genetic hearing loss ideally needs long-term gene expression studies to exclude any adverse events associated with the therapeutic genes.

Efficient control of the tetracycline-regulatory system is based on the specificity of the TetR/tetO interaction and the efficiency and safety of its inducers, such as tetracycline or Dox.^{43,44} Mutant tTA2s are composed of one TetR and three repeated oligonucleotides of the VP-16-derived minimal activation domain. In the Tet-on system, rTA2s-S2 showed a high activating ratio because its background expression level was lower than that of other mutants, such as rTA2s-M2, which despite having a higher activation potential had also a high initial background.²⁵ By using the mutant transactivator, Urlinger *et al.* demonstrated that stringent regulation of target genes could be achieved over a range of four to five orders of magnitude

in stably transfected HeLa cells.²⁴ These regulatory systems could be further optimized to offer several potential advantages. The tetracycline-dependent transcriptional silencer allows tight regulation of transgene expression by eliminating baseline leakage.^{20,45} Gene regulation mediated by rTA2s-S2 was substantially tighter when combined with active silencing by the tetracycline-dependent transcriptional silencer in the non-induced state.^{41,46}

Our results show that AAV1-mediated gene transfer is a promising gene delivery approach for the inner ear apparatus. To become an efficient and safe therapeutic method, it will be necessary to improve vector technology to achieve long-term transduction in a fail-safe system. We presented data demonstrating successful AAV-mediated transfer and modulation of transgene expression in the cochlea using a modified Tet-on system. In addition to the need for dosage control of neurotrophic factors, the AAV1 and the Tet-on system may be useful for the regulation of the expression of other therapeutic gene products in the cochlea. Following further improvements, the rAAV-mediated transduction system may be of potential use for cochlear gene therapy applications in humans.

MATERIALS AND METHODS

Construction and preparation of the plasmids. The AAV vector proviral plasmid pAAV2-CAG-EGFP-WPRE (pAAV2-EGFP) contained the EGFP gene under the control of the CAG promoter and the WPRE and was flanked by inverted terminal repeats. A BamHI fragment containing the GDNF flag complementary DNA was subcloned into this plasmid to obtain the pAAV2-CAG-GDNF-WPRE (pAAV2-GDNF) cassette.

The pAAV2-CMV-GDNF plasmid with the CMV promoter, the first intron of the human growth hormone gene, and the simian virus 40 polyadenylation signal sequence, were inserted between the inverted terminal repeats of the AAV type 2 genome.⁴⁷ The transactivator rTA2s-S2 complementary DNA in the pUHR161-1 plasmid (BD Biosciences, San Jose, CA) and the TRE in the pTRE-d2EGFP plasmid (BD Biosciences, CA) were subcloned together into the pAAV2-CMV-GDNF plasmid to obtain the AAV vector proviral plasmid pAAV2-rTA2s-S2-TRE-GDNF. A SacII-EcoRI fragment containing the d2EGFP complementary DNA from the pTRE-d2EGFP plasmid (BD Biosciences, CA) was subcloned into this plasmid to create the pAAV2-rTA2s-S2-TRE-EGFP plasmid (see **Supplementary Materials and Methods**).

Recombinant AAV vector production. The AAV1 vectors were produced as previously described by using a 293-cell transfection protocol²⁸ with the proviral plasmid pAAV2-EGFP, pAAV2-Luciferase,⁴⁸ pAAV2-GDNF, pAAV2-rTA2s-S2-TRE-EGFP, or pAAV2-rTA2s-S2-TRE-GDNF; the AAV packaging plasmid pAAV1RepCap; and the adenovirus helper plasmid pAdeno5 using an active gassing system.⁴⁹ The recombinant AAV2 expressing the *Escherichia coli* β -galactosidase gene under the control of the CMV promoter (AAV2-LacZ) was generated using the proviral plasmid pAAV-LacZ.⁵⁰ (see **Supplementary Materials and Methods**).

In vitro expression of GDNF. To detect the *in vitro* expression of the GDNF flag fusion protein, 293 cells were transduced with the AAV1-GDNF plasmid at 1×10^6 vector genome copies/cell. For the detection of the regulated expression, 293 cells were transduced with the AAV proviral plasmid pAAV2-rTA2s-S2-TRE-d2EGFP or pAAV2-rTA2s-S2-TRE-GDNF in the presence or absence of $1 \mu\text{mol/l}$ Dox-HCl (Sigma, St Louis, MO) (see **Supplementary Materials and Methods**).

Surgical procedures and cochlear perfusions. All animal studies were performed in accordance with the guidelines issued by the committee on animal research at Jichi Medical University. Twenty 5-week-old male Sprague-Dawley rats with normal Preyer's reflexes weighing 130–150 g

were utilized (CLEA Japan, Tokyo, Japan). Five-week-old male C57BL/6 mice were utilized for optical bioluminescence imaging. The animals were anesthetized with ketamine (50 mg/kg) and xylazine (5 mg/kg). A post-auricular approach was performed to expose the tympanic bony bulla. A small opening (2 mm in diameter) to the tympanic bulla was made by carefully drilling through the bone of the bulla to gain access to the round window membrane. Subsequently, $5 \mu\text{l}$ of AAV vector solution (AAV1-EGFP, AAV2-Luciferase, or AAV1-GDNF, 5×10^{10} genome copies, $n = 5$ each) was microinjected into the cochlea through the round window for over 10 minutes using a glass micropipette ($40 \mu\text{m}$ in diameter) fitted on a Univentor 801 syringe pump (Serial No. 170182, High Precision Instruments, Univentor Ltd., Malta). The rats were also injected with the AAV1-S2-GDNF in the presence ($n = 5$) or absence ($n = 5$) of Dox. A small plug of muscle was used to seal the cochlea, and the surgical wound was closed in layers and dressed with an antibiotic ointment.

Transgene expression in vivo. The rats were deeply anesthetized and the perilymph was sampled from the inoculated cochlea through the round window. GDNF protein levels were measured using a GDNF Emax ImmunoAssay System (Promega, Madison, WI) according to the manufacturer's instructions. The GDNF expression in the rat cochlea was determined by immunohistochemistry using an anti-FLAG antibody.

AAV2-LacZ or AAV2-S2-GDNF vector (1×10^{10} genome copies) was injected into the quadriceps of the C57BL/6 mice (6 weeks old, CLEA Japan, Tokyo, Japan). The mice were injected with phosphate-buffered saline ($n = 5$) or AAV2-LacZ ($n = 5$). Animals treated with various concentrations of Dox were injected with the AAV2-S2-GDNF ($n = 5$ per group). Two weeks after the transduction, animals were deeply anesthetized, and the injected muscle was sampled. The tissue levels of the GDNF protein were measured with an enzyme-linked immunosorbent assay kit (GDNF Emax ImmunoAssay System, Promega, WI), according to the manufacturer's instructions. The levels of GDNF were expressed as pg/mg protein. The assay sensitivity ranged from 16 to 1,000 pg/ml.

Two weeks after the injection of the AAV2-Luciferase, optical bioluminescence imaging was performed using the CCD camera (Xenogen, Alameda, CA). After intraperitoneal injection of reporter substrate D-Luciferin (375 mg/kg body weight), mice were imaged for scans.

Kanamycin administration and ABR assessment. A dose of 333 mg of kanamycin base/kg body weight was obtained by injecting $3 \mu\text{l/g}$ body weight. Seven days after virus injection, kanamycin was given subcutaneously twice daily for 12 consecutive days. The body weight of the animals was monitored daily to adjust the kanamycin dosages accordingly.

Auditory thresholds were determined by audiometry of evoked ABRs using Tucker-DAVIS Technologies and Scope software (Power Lab; ADInstruments, Colorado Springs, CO). Thresholds were evaluated for each animal prior to the start of the injection procedure and 2 days after the termination of kanamycin treatment. The ABRs were measured as previously described,⁷ using a two-way repeated analysis of variance (see **Supplementary Materials and Methods**).

Histological evaluation of the cochlear preservation. Cochlear hair cell loss was determined by F-actin staining. One month after transduction, the presence of the cochlear spiral ganglion neurons was determined by 4',6'-diamino-2-phenylindole dihydrochloride staining to visualize nuclear chromatin. After decalcification, $6 \mu\text{m}$ mid-modiolus cryosections of the cochlea from each animal were histologically analyzed. The number of spiral ganglion neurons was determined in every third section of the cochlear basal turn from the AAV1-transduced and kanamycin-treated rats (see **Supplementary Materials and Methods**).

Statistical analyses. Results are presented as the means \pm SD. Data were statistically analyzed using analysis of variance, paired student's *t*-test (injected versus contralateral sides) or unpaired student's *t*-test (therapy versus control groups) (StatView 5.0 software; SAS Institute, Cary, NC).

ACKNOWLEDGMENTS

The authors thank Avigen, (Alameda, CA) for providing the pAAV-LacZ and pAdeno. We also thank Thomas Hope (Department of Microbiology and Immunology, The University of Illinois at Chicago) for providing pBS II SK-WPRE-B11 and Jun-ichi Miyazaki (Osaka University Graduate School of Medicine, Osaka, Japan) for pCAGGS. The authors also thank Miyoko Mitsu for her encouragement and technical support. This work was supported in part by grants from the Ministry of Health, Labour and Welfare of Japan (Grants-in-Aid for Scientific Research and grant for 21 Century Centers of Excellence program) and the "High-Tech Research Center" Project for Private Universities (matching fund subsidy, from the Ministry of Education, Culture, Sports, Science, and Technology of Japan). The authors declare no conflict of interest.

SUPPLEMENTARY MATERIAL

Materials and Methods.

Figure S1. Bioluminescence of the transduced cochlea in living mice.

REFERENCES

- Wu, WJ, Sha, SH and Schacht, J (2002). Recent advances in understanding aminoglycoside ototoxicity and its prevention. *Audiol Neurootol* **7**: 171-174.
- Heller, WP, Wagstaff, SA, O'Leary, SJ and Shepherd, RK (2002). Functional and morphological response of the stria vascularis following a sensorineural hearing loss. *Hear Res* **172**: 127-136.
- Tsue, TT, Oesterle, EC and Rubel, EW (1994). Hair cell regeneration in the inner ear. *Otolaryngol Head Neck Surg* **111**: 281-301.
- Raphael, Y, Frislancho, JC and Roessler, BJ (1996). Adenoviral-mediated gene transfer into guinea pig cochlear cells in vivo. *Neurosci Lett* **207**: 137-141.
- Ishimoto, S, Kawamoto, K, Kanzaki, S and Raphael, Y (2002). Gene transfer into supporting cells of the organ of Corti. *Hear Res* **173**: 187-197.
- Okada, T, Nomoto, T, Shimazaki, K, Ujino, W, Lu, Y, Matsushita, T et al. (2002). Adeno-associated virus vectors for gene transfer to the brain. *Methods* **28**: 237-247.
- Liu, Y, Okada, T, Sheykholeslami, K, Shimazaki, K, Nomoto, T, Muramatsu, S et al. (2005). Specific and efficient transduction of cochlear inner hair cells with recombinant adeno-associated virus type 3 vector. *Mol Ther* **12**: 725-733.
- Lin, LF, Doherty, DH, Lile, JD, Bektesh, S and Collins, F (1993). GDNF: a glial cell line-derived neurotrophic factor for midbrain dopaminergic neurons. *Science* **260**: 1130-1132.
- Henderson, CE, Phillips, HS, Pollock, RA, Davies, AM, Lemuelle, C, Armanini, M et al. (1994). GDNF: a potent survival factor for motoneurons present in peripheral nerve and muscle. *Science* **266**: 1062-1064.
- Wang, Y, Lin, SZ, Chiu, AL, Williams, LR and Hoffman, BJ (1997). Glial cell line-derived neurotrophic factor protects against ischemia-induced injury in the cerebral cortex. *J Neurosci* **17**: 4341-4348.
- Keithley, EM, Ma, CL, Ryan, AF, Louis, JC and Magal, E (1998). GDNF protects the cochlea against noise damage. *Neuroreport* **9**: 2183-2187.
- Shoji, F, Yamasoba, T, Magal, E, Dolan, DF, Altschuler, RA and Miller, JM (2000). Glial cell line-derived neurotrophic factor has a dose dependent influence on noise-induced hearing loss in the guinea pig cochlea. *Hear Res* **142**: 41-55.
- Suzuki, M, Yagi, M, Brown, JN, Miller, AL, Miller, JM and Raphael, Y (2000). Effect of transgenic GDNF expression on gentamicin-induced cochlear and vestibular toxicity. *Gene Ther* **7**: 1046-1054.
- Yagi, M, Kanzaki, S, Kawamoto, K, Shin, B, Shah, PP, Magal, E et al. (2000). Spiral ganglion neurons are protected from degeneration by GDNF gene therapy. *J Assoc Res Otolaryngol* **1**: 315-325.
- Hakuba, N, Watabe, K, Hyodo, J, Ohashi, T, Eto, Y, Taniguchi, M et al. (2003). Adenovirus-mediated overexpression of a gene prevents hearing loss and progressive inner hair cell loss after transient cochlear ischemia in gerbils. *Gene Ther* **10**: 426-433.
- Kawamoto, K, Yagi, M, Stover, T, Kanzaki, S and Raphael, Y (2003). Hearing and hair cells are protected by adenoviral gene therapy with TGF-beta1 and GDNF. *Mol Ther* **7**: 484-492.
- Kuang, R, Hever, G, Zajic, G, Yan, Q, Collins, F, Louis, JC et al. (1999). Glial cell line-derived neurotrophic factor. Potential for otoprotection. *Ann NY Acad Sci* **884**: 270-291.
- Yagi, M, Magal, E, Sheng, Z, Ang, KA and Raphael, Y (1999). Hair cell protection from aminoglycoside ototoxicity by adenovirus-mediated overexpression of glial cell line-derived neurotrophic factor. *Hum Gene Ther* **10**: 813-823.
- Meng, X, Lindahl, M, Hyonen, ME, Parvinen, M, de Rooij, DG, Hess, MW et al. (2000). Regulation of cell fate decision of undifferentiated spermatogonia by GDNF. *Science* **287**: 1489-1493.
- Perez, N, Plence, P, Millet, V, Greuet, D, Minot, C, Noel, D et al. (2002). Tetracycline transcriptional silencer tightly controls transgene expression after in vivo intramuscular electrotransfer: application to interleukin 10 therapy in experimental arthritis. *Hum Gene Ther* **13**: 2161-2172.
- Regulier, E, Pereira de Almeida, L, Sommer, B, Aebischer, P and Deglon, N (2002). Dose-dependent neuroprotective effect of ciliary neurotrophic factor delivered via tetracycline-regulated lentiviral vectors in the quinolinic acid rat model of Huntington's disease. *Hum Gene Ther* **13**: 1981-1990.
- Rubinck, S, Woratanadham, J, Yu, H and Dong, JY (2005). New complex Ad vectors incorporating both rTA and tTS deliver tightly regulated transgene expression both in vitro and in vivo. *Gene Ther* **12**: 504-511.
- Pluta, K, Luce, MJ, Bao, L, Agha-Mohammadi, S and Reiser, J (2005). Tight control of transgene expression by lentiviral vectors containing second-generation tetracycline-responsive promoters. *J Gene Med* **7**: 803-817.
- Urlinger, S, Baron, U, Thellmann, M, Hasan, MT, Bujard, H and Hillen, W (2000). Exploring the sequence space for tetracycline-dependent transcriptional activators: novel mutations yield expanded range and sensitivity. *Proc Natl Acad Sci USA* **97**: 7963-7968.
- Lamartina, S, Roscillo, G, Rinaudo, CD, Sporeno, E, Sivi, L, Hillen, W et al. (2002). Stringent control of gene expression in vivo by novel doxycycline-dependent trans-activators. *Hum Gene Ther* **13**: 199-210.
- Okada, T, Shimazaki, K, Nomoto, T, Matsushita, T, Mizukami, H, Urabe, M et al. (2002). Adeno-associated viral vector-mediated gene therapy of ischemia-induced neuronal death. *Methods Enzymol* **346**: 378-393.
- Stone, IM, Lurie, DI, Kelley, MW and Poulson, DJ (2005). Adeno-associated virus-mediated gene transfer to hair cells and support cells of the murine cochlea. *Mol Ther* **11**: 843-848.
- Liu, Y, Okada, T, Nomoto, T, Ke, X, Kume, A, Ozawa, K et al. (2007). Promoter effects of adeno-associated viral vector for transgene expression in the cochlea in vivo. *Exp Mol Med* **39**: 170-175.
- Oppenheim, RW (1997). Related mechanisms of action of growth factors and antioxidants in apoptosis: an overview. *Adv Neural* **72**: 69-78.
- Pruska, BM and Schacht, J (1995). Formation of free radicals by gentamicin and iron and evidence for an iron/gentamicin complex. *Biochem Pharmacol* **50**: 1749-1752.
- Sha, SH and Schacht, J (1999). Stimulation of free radical formation by aminoglycoside antibiotics. *Hear Res* **128**: 112-118.
- Sanicola, M, Hession, C, Worley, D, Carmillo, P, Ehrenfels, C, Walus, L et al. (1997). Glial cell line-derived neurotrophic factor-dependent RET activation can be mediated by two different cell-surface accessory proteins. *Proc Natl Acad Sci USA* **94**: 6238-6243.
- Ylikoski, J, Pirvola, U, Virkkala, J, Suvalo, P, Liang, XQ, Magal, E et al. (1998). Guinea pig auditory neurons are protected by glial cell line-derived growth factor from degeneration after noise trauma. *Hear Res* **124**: 17-26.
- Nam, YJ, Stover, T, Hartman, SS and Altschuler, RA (2000). Upregulation of glial cell line-derived neurotrophic factor (GDNF) in the rat cochlea following noise. *Hear Res* **146**: 1-6.
- Kho, ST, Pettis, RM, Mhatre, AN and Lalwani, AK (2000). Safety of adeno-associated virus as cochlear gene transfer vector: analysis of distant spread beyond injected cochlea. *Mol Ther* **2**: 368-373.
- Favre, D, Blouin, V, Provost, N, Spisek, R, Porrot, F, Bohl, D et al. (2002). Lack of an immune response against the tetracycline-dependent transactivator correlates with long-term doxycycline-regulated transgene expression in non-human primates after intramuscular injection of recombinant adeno-associated virus. *J Virol* **76**: 11605-11611.
- Latta-Mahieu, M, Rolland, M, Caillet, C, Wang, M, Kennel, P, Mahfouz, I et al. (2002). Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. *Hum Gene Ther* **13**: 1611-1620.
- Lena, AM, Giannetti, P, Sporeno, E, Ciliberto, G and Savino, R (2005). Immune responses against tetracycline-dependent transactivators affect long-term expression of mouse erythropoietin delivered by a helper-dependent adenoviral vector. *J Gene Med* **7**: 1086-1096.
- Cordier, L, Gao, GP, Hack, AA, McNally, EM, Wilson, JM, Chirmule, N et al. (2001). Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. *Hum Gene Ther* **12**: 205-215.
- McGee Salfnter, LH, Rendahl, KG, Quiroz, D, Coyne, M, Ladner, M, Manning, WC et al. (2001). Recombinant AAV-mediated delivery of a tet-inducible reporter gene to the rat retina. *Mol Ther* **3**: 688-696.
- Lamartina, S, Sivi, L, Roscillo, G, Casimiro, D, Simon, AJ, Davies, ME et al. (2003). Construction of an rTA2(s)-m2/TS(kid)-based transcription regulatory switch that displays no basal activity, good inducibility, and high responsiveness to doxycycline in mice and non-human primates. *Mol Ther* **7**: 271-280.
- Srouf, MA, Fechner, H, Wang, X, Siemietzki, U, Albert, T, Oldenburg, J et al. (2003). Regulation of human factor IX expression using doxycycline-inducible gene expression system. *Thromb Haemostasis* **90**: 398-405.
- Kistner, A, Gossen, M, Zimmermann, F, Jerecic, I, Ullmer, C, Lubbert, H et al. (1996). Doxycycline-mediated quantitative and tissue-specific control of gene expression in transgenic mice. *Proc Natl Acad Sci USA* **93**: 10933-10938.
- Knott, A, Garke, K, Urlinger, S, Gultmann, J, Muller, Y, Thellmann, M et al. (2002). Tetracycline-dependent gene regulation: combinations of transregulators yield a variety of expression windows. *Biotechniques* **32**: 796, 798, 800 passim.
- Rendahl, KG, Quiroz, D, Ladner, M, Coyne, M, Seltzer, J, Manning, WC et al. (2002). Tightly regulated long-term erythropoietin expression in vivo using tet-inducible recombinant adeno-associated viral vectors. *Hum Gene Ther* **13**: 335-342.
- Salucci, V, Scarito, A, Aurisicchio, L, Lamartina, S, Nicolaou, G, Ciampallo, S et al. (2002). Tight control of gene expression by a helper-dependent adenovirus vector carrying the rTA2(s)-M2 tetracycline transactivator and repressor system. *Gene Ther* **9**: 1415-1421.
- Wang, L, Muramatsu, S, Lu, Y, Ikeguchi, K, Fujimoto, K, Okada, T et al. (2002). Delayed delivery of AAV-GDNF prevents nigral neurodegeneration and promotes functional recovery in a rat model of Parkinson's disease. *Gene Ther* **9**: 381-389.
- Okada, T, Uchibori, R, Iwata-Okada, M, Takahashi, M, Nomoto, T, Nonaka-Sarukawa, M et al. (2006). A histone deacetylase inhibitor enhances recombinant adeno-associated virus-mediated gene expression in tumor cells. *Mol Ther* **13**: 738-746.
- Okada, T, Nomoto, T, Yoshioka, T, Nonaka-Sarukawa, M, Ito, T, Ogura, T et al. (2005). Large-scale production of recombinant viruses by use of a large culture vessel with active gassing. *Hum Gene Ther* **16**: 1212-1218.
- Okada, T, Mizukami, H, Urabe, M, Nomoto, T, Matsushita, T, Hanazono, Y et al. (2001). Development and characterization of an antisense-mediated prepackaging cell line for adeno-associated viral vector production. *Biochem Biophys Res Commun* **288**: 62-68.

Protection Against Aminoglycoside-induced Ototoxicity by Regulated AAV Vector-mediated GDNF Gene Transfer Into the Cochlea

Yuhe Liu^{1,2,3}, Takashi Okada^{1,4}, Kuniko Shimazaki⁵, Kianoush Sheykholslami⁶, Tatsuya Nomoto¹, Shin-Ichi Muramatsu⁷, Hiroaki Mizukami¹, Akihiro Kume¹, Shuifang Xiao³, Keiichi Ichimura² and Keiya Ozawa¹

¹Division of Genetic Therapeutics, Jichi Medical University, Tochigi, Japan; ²Department of Otolaryngology, Jichi Medical University, Tochigi, Japan; ³Department of Otolaryngology, Peking University First Hospital, Beijing, China; ⁴Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, Tokyo, Japan; ⁵Department of Physiology, Jichi Medical University, Tochigi, Japan; ⁶Department of Neurobiology, Northeastern Ohio Universities College of Medicine, Rootstown, Ohio, USA; ⁷Division of Neurology, Department of Medicine, Jichi Medical University, Tochigi, Japan

Since standard aminoglycoside treatment progressively causes hearing disturbance with hair cell degeneration, systemic use of the drugs is limited. Adeno-associated virus (AAV)-based vectors have been of great interest because they mediate stable transgene expression in a variety of postmitotic cells with minimal toxicity. In this study, we investigated the effects of regulated AAV1-mediated glial cell line-derived neurotrophic factor (GDNF) expression in the cochlea on aminoglycoside-induced damage. AAV1-based vectors encoding GDNF or vectors encoding GDNF with an rtTA2s-S2 Tet-on regulation system were directly microinjected into the rat cochlea through the round window at 5×10^{10} genome copies/body. Seven days after the virus injection, a dose of 333 mg/kg of kanamycin was subcutaneously given twice daily for 12 consecutive days. GDNF expression in the cochlea was confirmed and successfully modulated by the Tet-on system. Monitoring of the auditory brain stem response revealed an improvement of cochlear function after GDNF transduction over the frequencies tested. Damaged spiral ganglion cells and hair cells were significantly reduced by GDNF expression. Our results suggest that AAV1-mediated expression of GDNF using a regulated expression system in the cochlea is a promising strategy to protect the cochlea from aminoglycoside-induced damage.

Received 12 May 2007; accepted 15 November 2007; published online 8 January 2008. doi:10.1038/sj.gt.6300379

INTRODUCTION

Aminoglycoside antibiotics are frequently used in empiric therapy for serious infections, such as septicemia, complicated intra-abdominal infections, complicated urinary tract infections, and nosocomial respiratory tract infections. However, it is well known

that aminoglycosides are associated with severe side effects, such as ototoxicity and nephrotoxicity, which attack the cochlea or vestibule and destroys the auditory and vestibular hair cells that pass information to the auditory nerve.¹ In addition, aminoglycosides predominantly destroy the outer hair cells by ototoxicity. Although the exact mechanism of damage is not well established,² aminoglycoside-induced hair cell loss results in a permanent hearing deficit³ that can progressively occur 6 months to a year after exposure to these drugs. Therefore, the development of a strategy to prevent aminoglycoside-associated ototoxicity before adverse events occur is a critical issue in clinical settings.

The expression of a transgene using viral vectors is a potential approach to introduce neurotrophic factors into the cochlea to prevent and treat aminoglycoside-induced hearing loss. However, most of the currently used vectors, such as adenovirus vectors or herpes simplex virus vectors, have an associated vector-related cytotoxicity.^{4,5} Hence, adeno-associated virus (AAV) vectors may be good candidates for gene transfer into the cochlear cells because of their efficient transduction and their safety and potential in long-term expression.⁶ We have previously demonstrated that an AAV1-based vector efficiently transduced the inner hair cells, the spiral ganglion cells, and many other types of cells.⁷ Therefore, an AAV1-based vector should successfully introduce secretory proteins, such as glial cell line-derived neurotrophic factor (GDNF), into the cochlea to prevent aminoglycoside-induced ototoxicity.

GDNF, a member of the transforming growth factor β family, was initially identified as a survival factor for mid-brain dopaminergic neurons and for a wide range of neuronal populations in the central and peripheral nervous systems.⁸⁻¹⁰ Although it is still unclear whether GDNF protects against ototoxicity, sustained infusion of recombinant GDNF protected the cochlear structure and function from noise- and drug-induced damage and stress,¹¹⁻¹⁸ although its half-life is very short. However, an overdose of GDNF was shown to enhance the sensitivity of the cochlea to insult and

Correspondence: Takashi Okada, Department of Molecular Therapy, National Institute of Neuroscience, National Center of Neurology and Psychiatry, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8551, Japan. E-mail: t-okada@ncnp.go.jp; Keiya Ozawa, Division of Genetic Therapeutics, Center for Molecular Medicine, Jichi Medical University, 3311-1 Yakushiji, Shimotsuke, Tochigi 329-0498, Japan. E-mail: kozawa@jichi.ac.jp

to destroy cochlear function.¹² Furthermore, it has been reported that testicular tumors are formed in GDNF-overexpressing mice.¹⁹ Therefore, an appropriate regulation system is required to realize the therapeutic benefits of GDNF expression.

Regulated transgene expression has been successfully achieved in various gene therapy experiments using the Tet system.^{20–23} Notably, tetracycline derivatives, such as doxycycline (Dox), activate the Tet-on system at doses 100-fold lower than tetracycline. Furthermore, the reverse Tet-responsive transcriptional activator (rtTA) series were improved through the generation of variants called rtTA2s-S2, which showed lower leakiness and better inducibility in HeLa cells and mice.^{24,25}

In this study, we describe *in vivo* therapeutic experiments utilizing AAV1 vector-mediated tetracycline-regulated expression of GDNF in cochlea. We demonstrate that AAV1 vector-mediated GDNF expression protects sensory cells in the inner ear from drug-induced degeneration.

RESULTS

Expression and distribution of transgene in the cochlea

AAV1-EGFP or AAV1-GDNF containing either the enhanced humanized green fluorescent protein (EGFP) gene or the GDNF gene under the control of the CAG (human cytomegalovirus (CMV) immediate-early enhancer and Chicken β -actin promoter) promoter, and the Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) (Figure 1a), was injected into the cochlea. The GDNF protein level in the perilymph was measured by enzyme-linked immunosorbent assay (Figure 2a). There was a significant increase in GDNF concentration in the cochlea transduced with AAV1-GDNF. The widespread distribution of the GDNF expression was observed in the cochlea, including the spiral ganglion and the inner hair cells (Figure 2b).

To examine the possible transduction of the contralateral ear with the virus diffusion, we analyzed the AAV vector-mediated




Figure 1 Schematic representation of the viral vectors used in this study. (a) An adeno-associated virus 1 (AAV1)-based vector was constructed using the CAG promoter to drive enhanced green fluorescent protein (EGFP) or mouse glial cell line-derived neurotrophic factor (GDNF) with a FLAG tag (GDNFflag). The Woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was inserted into the 3' end of the transgene cassette. (b) The transactivator rtTA2s-S2 is under the control of the CMV promoter. The minimal CMV promoter (PminCMV) induces transgene expression (EGFP or GDNFflag) in combination with the Tetracycline-responsive element (TRE) and transactivator. CAG, human cytomegalovirus immediate-early enhancer and Chicken β -actin promoter; CMV, cytomegalovirus immediate-early promoter; pA, the simian virus 40 polyadenylation sequences; ITR, inverted terminal repeat from AAV2.

transgene expression of the rodents with this transduction approach using the optical bioluminescence imaging. Luciferase expression was mainly detected at the injected side of the cochlea (5,370.3 photons/sec/cm²/sr, **Supplementary Figure S1**). Interestingly, the AAV vector also transduced the contralateral ear (876.8 photons/sec/cm²/sr), along with the brain (792.9 photons/sec/cm²/sr). Similar results were obtained with repeated experiments.

Preservation of the hair cells and spiral ganglion cells in the cochlea

Hair cell loss in the whole-mount cochlea of all the tested rat groups was analyzed by F-actin staining with rhodamine-phalloidin. Figure 3a shows a representative dissection through the second turn of the rat cochlea, in which a full complement of hair cells is revealed by F-actin phalloidin staining. In the vehicle-treated control group, outer hair cells in the base and middle turn were drastically lost after kanamycin treatment (Figure 3b). In the AAV1-GDNF/kanamycin-treated group, successful protection of the hair cells in the cochlea was observed (Figure 3c). In the contralateral cochlea, some of outer hair cells were also protected (Figure 3d). The spiral ganglion cell loss in the basal turn of the cochlea was assessed using 4',6'-diamino-2-phenylindole dihydrochloride staining (Figure 4a and b). Survival of the spiral ganglion cells in the AAV1-GDNF injected cochlea was significantly improved compared to that in the AAV1-EGFP injected cochlea (Figure 4c).

Protection of cochlear function by GDNF

Auditory brain stem response (ABR) recordings of the aminoglycoside-treated animals were performed to examine hearing




Figure 2 Expression and distribution of transgene in the cochlea. (a) Cochlear glial cell line-derived neurotrophic factor (GDNF) expression levels were measured by enzyme-linked immunosorbent assay in the transduced rats. GDNF expression level of the perilymph in the AAV1-GDNF/kanamycin group was significantly higher than that in the control group ($n = 5$, $P < 0.001$). (b) Immunohistochemistry was performed to analyze the expression of the GDNFflag in the rat cochlea. The AAV1-EGFP-transduced cochlea was used as a control (left). Cochlear sections were prepared after AAV1-GDNF injection and kanamycin administration. GDNFflag expression was detected in the cochlea with an anti-FLAG antibody (right). Scale bar = 25 μ m; $\times 400$. AAV1, adeno-associated virus 1; EGFP, enhanced green fluorescent protein.




Figure 3 Preservation of the hair cells in the transduced cochlea. Hair cell loss in the cochlea of transduced rats was analyzed by F-actin staining. The dissected samples were dissected from the middle turn of the cochlea. The adeno-associated virus 1 (AAV1) vector was injected into the scala tympani of the cochlea prior to 12 days of kanamycin administration. (a) The normal cochlea. (b) The cochlea from the vehicle-treated ear; the many dark spaces represent the loss of outer hair cells. (c) The cochlea from the AAV1-GDNF-transduced ear. (d) The cochlea from the contralateral ear of AAV1-GDNF transduced rats. GDNF, glial cell line-derived neurotrophic factor.




Figure 4 Survival of the spiral ganglion cells in the transduced cochlea. AAV1-GDNF-mediated rescue of the kanamycin-induced damage to the rat spiral ganglion neurons (SGNs): 4',6-diamino-2-phenylindole dihydrochloride (DAPI) staining was performed on the sections obtained from the rat pretreated with either AAV1-EGFP or AAV1-GDNF, followed by kanamycin injections. (a, b) Representative photomicrographs of the cryosections showing the basal turn of the cochlear spiral (a, AAV1-EGFP; b, AAV1-GDNF). (c) The number of DAPI-positive large-nucleus cells that exhibited SGN morphology was counted. An asterisk denotes a statistically significant difference between the AAV1-GDNF and AAV1-EGFP-transduced rats (*t*-test, $P < 0.001$). AAV1, adeno-associated virus 1; EGFP, enhanced green fluorescent protein; glial cell line-derived neurotrophic factor.

impairment. At all frequencies tested, both GDNF-transduced and contralateral, untreated ears showed a significant improvement in the threshold shifts compared to the ears transduced with EGFP ($n = 5$, $P < 0.05$) (Figure 5). In the EGFP group, there was




Figure 5 Protection of cochlear function by glial cell line-derived neurotrophic factor GDNF. Auditory brain stem response (ABR) threshold shifts (mean \pm SD) of the (a) treated and (b) untreated ears at each tested frequency in the enhanced green fluorescent protein (EGFP) and GDNF transduced rats. The ABR threshold was measured twice in all the animals. The ears treated with AAV1-GDNF showed a significant improvement in the threshold shifts compared to the ears treated with AAV1-EGFP at all frequencies tested ($n = 5$, $P < 0.05$). Arrows indicate the average ABR thresholds that exceeded the output power of the ABR apparatus. AAV1, adeno-associated virus 1.

no significant difference in the ABR threshold shifts between the transduced and contralateral, untreated cochleae at all frequencies tested. Animals transduced with the AAV1-GDNF demonstrated lower ABR threshold shifts in the injected side compared to the contralateral side (at 12, 16, 20, 24 kHz; $P < 0.05$). These data indicate that both ears were protected even if the AAV1-GDNF was only injected into one ear.

Induced transgene expression

Two hundred and ninety three cells were transduced with the proviral plasmid harboring rTA2s-S2 and the tetracycline-responsive element (TRE) to express the EGFP gene (Figure 1b). In the presence of Dox, a significant level of fluorescence was detected, suggesting that the rTA2s-S2 system could switch on transcription following Dox treatment (Figure 6a). In contrast, reporter gene expression in the cultured cells was faint in the absence of Dox, indicating a low basal activity *in vitro*. Western blot analysis of GDNF showed that the transgene was induced in the presence of Dox, while no expression was detected in the absence of Dox (Figure 6b).

In vivo induction of GDNF expression and the dose-response to Dox

Enzyme-linked immunosorbent assay analysis of the GDNF expression level in muscle also showed low basal activity and induced expression after Dox treatment (Figure 6c). In the absence of Dox, the expression level of GDNF in the AAV2-S2-GDNF group was as low as that in the phosphate-buffered saline and AAV2-LacZ groups. On the other hand, significant increases in the GDNF level were observed in the muscle with increasing amounts of Dox, demonstrating that the rTA2s-S2 system induces gene expression in a dose-dependent manner.

Inducible GDNF expression in the cochlea

Extensive inducible GDNF transgene expression was confirmed by immunohistochemistry using an anti-FLAG-antibody in the AAV1-S2-GDNF/kanamycin group in the presence of Dox (Figure 7).